“With the antiviral pill, Merck hopefully can take what ... be available in the market by late this year. The US government has promised to purchase 1.7 million courses of treatment at $700 ...
While the US government is paying $712 per treatment course, Merck is allowing generic manufacturers to make its pill for lower-income markets, where they will likely charge a fraction of that cost.
The company paid US$200 per share, more than 70% above the Prometheus's closing share price on April 14, before the acquisition was announced on April 16. The majority of the offering contains special ...
Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year ... the U.S. government agreed to buy molnupiravir if the FDA recommends ...
But US authorities recently made an advance purchase of 1.7 million ... also made purchase agreements. Merck is the first company to report trial results of a pill to treat Covid, but other ...
The company paid US$200 per share, more than 70% above the Prometheus's closing share price on April 14, before the acquisition was announced on April 16. The majority of the offering contains special ...
On Nov 4, Britain was the first country in the world to approve the potential antiviral pill developed jointly by Merck & Co Inc and Ridgeback Biotherapeutics, both based in the US. Molnupiravir ...
The move comes after Merck filed for emergency approvals of molnupiravir in the US, Europe and Canada on the back of clinical trial data showing it was able to halve the risk of hospitalisation or ...
Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Merck Animal Health, Richard DeLuca, for US$4.6m worth ... insiders didn't buy any shares ...